Swift Wendy, Gates Peter, Dillon Paul
National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, 2052, Australia.
Harm Reduct J. 2005 Oct 4;2:18. doi: 10.1186/1477-7517-2-18.
The New South Wales State Government recently proposed a trial of the medical use of cannabis. Australians who currently use cannabis medicinally do so illegally and without assurances of quality control. Given the dearth of local information on this issue, this study explored the experiences of medical cannabis users.
Australian adults who had used cannabis for medical purposes were recruited using media stories. A total of 147 respondents were screened by phone and anonymous questionnaires were mailed, to be returned by postage paid envelope.
Data were available for 128 participants. Long term and regular medical cannabis use was frequently reported for multiple medical conditions including chronic pain (57%), depression (56%), arthritis (35%), persistent nausea (27%) and weight loss (26%). Cannabis was perceived to provide "great relief" overall (86%), and substantial relief of specific symptoms such as pain, nausea and insomnia. It was also typically perceived as superior to other medications in terms of undesirable effects, and the extent of relief provided. However, nearly one half (41%) experienced conditions or symptoms that were not helped by its use. The most prevalent concerns related to its illegality. Participants reported strong support for their use from clinicians and family. There was almost universal interest (89%) in participating in a clinical trial of medical cannabis, and strong support (79%) for investigating alternative delivery methods.
Australian medical cannabis users are risking legal ramifications, but consistent with users elsewhere, claim moderate to substantial benefits from its use in the management of their medical condition. In addition to strong public support, medical cannabis users show strong interest in clinical cannabis research, including the investigation of alternative delivery methods.
新南威尔士州政府最近提议对大麻的医疗用途进行试验。目前在澳大利亚,将大麻用于医疗目的属于非法行为,且无法保证质量控制。鉴于当地在这个问题上缺乏相关信息,本研究探讨了医用大麻使用者的经历。
通过媒体报道招募曾将大麻用于医疗目的的澳大利亚成年人。通过电话对总共147名受访者进行筛选,并邮寄匿名问卷,问卷通过邮资已付的信封返还。
有128名参与者的数据可供分析。经常有报告称,长期且规律地使用医用大麻用于多种医疗状况,包括慢性疼痛(57%)、抑郁症(56%)、关节炎(35%)、持续性恶心(27%)和体重减轻(26%)。总体而言,大麻被认为能带来“极大缓解”(86%),并能显著缓解疼痛、恶心和失眠等特定症状。在不良影响以及缓解程度方面,它通常也被认为优于其他药物。然而,近一半(41%)的人经历了使用大麻并未改善的状况或症状。最普遍的担忧与大麻的非法性有关。参与者报告称,临床医生和家人对他们使用大麻给予了大力支持。几乎所有人都有兴趣(89%)参与医用大麻的临床试验,并且大力支持(79%)研究替代给药方式。
澳大利亚的医用大麻使用者面临法律后果风险,但与其他地方的使用者一样,声称在使用大麻管理自身医疗状况方面有中度到显著的益处。除了公众的大力支持外,医用大麻使用者对临床大麻研究表现出浓厚兴趣,包括对替代给药方式的研究。